Gefitinib and afatinib show potential efficacy for Fanconi anemia-related head and neck cancer.

CONCLUSIONS: Our data present a complete preclinical analysis and promising therapeutic line of the first FDA/EMA approved anticancer drugs exerting cancer specific toxicity for HNSCC in FA patients.
PMID: 32005748 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 30, 2020 Category: Cancer & Oncology Authors: Montanuy H, Martínez-Barriocanal A, Casado JA, Rovirosa L, Ramírez MJ, Nieto R, Carrascoso-Rubio C, Riera P, Gonzalez A, Lerma E, Lasa A, Carreras-Puigvert J, Helleday T, Bueren JA, Arango D, Minguillón J, Surrallés J Tags: Clin Cancer Res Source Type: research